✦ LIBER ✦

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

✍ Scribed by Choon-Kee Lee; Ashraf Badros; Bart Barlogie; Christopher Morris; Maurizio Zangari; Athanasios Fassas; Frits van Rhee; Michele Cottler-Fox; Joth Jacobson; Raymond Thertulien; Firas Muwalla; Syed Mazher; Elias Anaissie; Guido Tricot

Book ID: 114216953
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 132 KB
Volume: 31
Category: Article
ISSN: 0301-472X
DOI: 10.1016/s0301-472x(02)01010-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide plus donor-lymphocytes infu

Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma

✍ Jean El-Cheikh; Roberto Crocchiolo; Sabine Furst; Patrick Ladaique; Luca Castagn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 338 KB

Comparable outcomes between unrelated an

Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma

✍ Jean El-Cheikh; Roberto Crocchiolo; Jean-Marie Boher; Sabine Furst; Anne-Marie S 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

Reduced-intensity conditioning allogenei

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients

✍ Pérez-Simón, J A; Sureda, A; Fernández-Aviles, F; Sampol, A; Cabrera, J R; Cabal 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 92 KB

Fludarabine/melphalan conditioning for a

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

✍ Giralt, S; Aleman, A; Anagnostopoulos, A; Weber, D; Khouri, I; Anderlini, P; Mol 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 93 KB

Allogeneic hsct with reduced intensity c

Allogeneic hsct with reduced intensity conditioning regimens in high risk patients with myelofibrosis

✍ D. Rondelli; G. Barosi; A. Bacigalupo; J.T. Prchal; U. Popat; E.P. Alessandrino; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Risk-factors of melphalan/fludarabine do

Risk-factors of melphalan/fludarabine dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ N. Kroger; J.A. Perez-Simon; H. Myint; H. Klingemann; A. Shimoni; A. Nagler; R. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB